Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Assets: 2015-2025

Historic Other Non-Current Assets for Cartesian Therapeutics (RNAC) over the last 7 years, with Sep 2025 value amounting to $5.6 million.

  • Cartesian Therapeutics' Other Non-Current Assets rose 232.59% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 232.59%. This contributed to the annual value of $1.7 million for FY2024, which is 21.21% up from last year.
  • Cartesian Therapeutics' Other Non-Current Assets amounted to $5.6 million in Q3 2025, which was down 0.00% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Other Non-Current Assets registered a high of $6.1 million during Q1 2025, and its lowest value of $1.3 million during Q4 2022.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.7 million (2024), whereas its average is $2.6 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Other Non-Current Assets dropped by 13.94% in 2023, and later skyrocketed by 339.58% in 2025.
  • Cartesian Therapeutics' Other Non-Current Assets (Quarterly) stood at $1.4 million in 2021, then fell by 4.93% to $1.3 million in 2022, then rose by 5.03% to $1.4 million in 2023, then climbed by 21.21% to $1.7 million in 2024, then spiked by 232.59% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $5.6 million for Q2 2025, and $6.1 million during Q1 2025.